|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ISRCTN |
|
Last refreshed on:
|
13 January 2015 |
|
Main ID: |
ISRCTN47583497 |
|
Date of registration:
|
09/02/2005 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Decreased time on mechanical ventilation when comparing analgesia-based sedation using remifentanil versus standard hypnotic-based sedation for up to 10 days in intensive care unit patients: a randomised trial.
|
|
Scientific title:
|
|
|
Date of first enrolment:
|
07/06/2002 |
|
Target sample size:
|
0 |
|
Recruitment status: |
Completed |
|
URL:
|
http://isrctn.com/ISRCTN47583497 |
|
Study type:
|
Interventional |
|
Study design:
|
Randomised controlled trial (Treatment)
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
Austria
|
Belgium
|
Denmark
|
France
|
Germany
|
Greece
|
Iran
|
Netherlands
|
|
Portugal
|
United Arab Emirates
| | | | | | |
|
Contacts
|
|
Name:
|
|
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
|
|
|
Name:
|
Andrew
Kirkham |
|
Address:
|
GlaxoSmithKline
Greenford Road
UB6 OHE
Greenford, Middlesex
United Kingdom |
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
|
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: Critically ill patients requiring 3-10 days of mechanical ventilation.
Exclusion criteria: Not provided at time of registration
Age minimum:
Age maximum:
Gender:
Not Specified
|
|
Health Condition(s) or Problem(s) studied
|
Medical or surgical patients requiring intensive care.
Surgery
Medical or surgical patients requiring intensive care.
|
|
Intervention(s)
|
|
Comparing analgesia-based sedation using remifentanil versus standard hypnotic-based sedation for up to 10 days in intensive care unit patients. Titration of analgesia/sedation to achieve optimal sedation. Regular assessments of haemodynamics.
|
|
Primary Outcome(s)
|
|
Not provided at time of registration
|
|
Secondary Outcome(s)
|
|
Not provided at time of registration
|
|
Source(s) of Monetary Support
|
|
GlaxoSmithKline (GSK)
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|